GSK (LON:GSK) Sets New 12-Month Low – Should You Sell?

GSK plc (LON:GSK) reached a new 52-week low on Wednesday. The stock traded as low as GBX 1,380.50 and last traded at GBX 1,790.50, with a volume of 5175766 shares trading hands. The stock had previously closed at GBX 1,765.50.

Analysts Set New Price Targets

GSK has been the topic of several research reports. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a research note on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research report on Tuesday, September 29th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Finally, Berenberg Bank boosted their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research report on Tuesday, September 15th. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, GSK currently has an average rating of “Hold” and an average price target of GBX 2,064.38.

GSK Stock Performance

The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82. The firm’s 50-day moving average price is GBX 1,861.99 and its two-hundred day moving average price is GBX 1,934.53. The firm has a market capitalization of £70.77 billion, a price-to-earnings ratio of 14.99, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last posted its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Sell-side analysts predict that GSK plc will post 175.980975 earnings per share for the current year.

Insider Activity at GSK

In related news, insider Jonathan Symonds bought 1,500 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was acquired at an average cost of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal purchased 637 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was bought at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Over the last quarter, insiders bought 2,144 shares of company stock worth $6,009,566. Corporate insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.